Physician profile
David S Wolf
NPI 1386879534
$10,295.69
in general payments reported to CMS, 2019-2025
38 companies · $1,560 in 2025
The $1,560 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,777 · 2020: $1,258 · 2021: $1,160 · 2022: $1,180 · 2023: $1,633 · 2024: $1,728 · 2025: $1,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,822 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,821.71 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,575.55 | 2019-2025 | Linzess, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,875.81 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,022.44 | 2019-2025 | Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $966.92 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $691.61 | 2021-2024 | Zeposia |
| Genzyme Corporation | $311.26 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $288.74 | 2019-2023 | Rebyota |
| Pfizer INC. | $282.73 | 2019-2025 | |
| Romark Laboratories, Lc | $281.37 | 2019-2020 | |
| Ardelyx, INC. | $273.11 | 2023-2025 | Ibsrela |
| Braintree Laboratories, INC. | $209.45 | 2019-2023 | Sutab |
| Phathom Pharmaceuticals, INC. | $164.28 | 2024 | Voquezna |
| Allergan, INC. | $162.90 | 2019-2020 | |
| Daiichi Sankyo INC. | $113.40 | 2019-2021 | |
| Redhill Biopharma INC. | $103.89 | 2021-2023 | Talicia, Aemcolo, Movantik |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $95.08 | 2025 | Zenpep, Vowst |
| Lilly USA, LLC | $90.23 | 2025 | Omvoh |
| Gilead Sciences, INC. | $78.68 | 2021-2022 | |
| Ucb, INC. | $78.62 | 2019 | |
| Evoke Pharma, INC. | $75.46 | 2022-2024 | Gimoti |
| Amgen INC. | $73.54 | 2019-2024 | Prolia, Evenity |
| Shire North American Group INC | $56.28 | 2019 | |
| Vivus LLC | $51.56 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $44.22 | 2019 | |
| Astellas Pharma US INC | $41.20 | 2020 | |
| Nestle Healthcare Nutrition INC. | $35.97 | 2022 | |
| Celltrion USA INC. | $35.72 | 2025 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $32.65 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28.86 | 2019 | |
| Azurity Pharmaceuticals, INC. | $24.75 | 2025 | Edarbi |
| Hitachi Healthcare Americas Corp. | $20.98 | 2019 | |
| Vibrant Gastro, INC. | $18.34 | 2023 | Vibrant Starter Kit |
| Alfasigma USA, INC. | $17.97 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.96 | 2023 | Livalo, Seglentis |
| Merck Sharp & Dohme LLC | $15.44 | 2019 | |
| Genentech USA, INC. | $15.21 | 2019 | |
| Novo Nordisk INC | $13.40 | 2022 | |
| Ibsa Pharma INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.